Apr. 23 at 4:01 PM
$GLUE quietly setting up — not a hype move, more like a positioning phase into the next few weeks.
Here’s what stands out:
Strategic deal with
$NVS:
$120M upfront + potential
$5.7B milestones/royalties — that’s real validation, not fluff.
Recent offering priced at 24 — gives a clear reference level institutions were willing to step in.
Data comps drawing parallels to
$VTYX (takeout story still fresh in biotech memory).
Smart money involved: Baker Bros, NEA, Suvretta, TCG — these guys don’t chase, they build early.
This isn’t a chase setup — it’s a scale-in name on weakness.
Watching for higher lows + volume expansion as confirmation. If biotech sentiment turns, this could reprice quickly.
Curious about the full approach?👉 Check the @MeanReverter_
